Navigation Links
ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
Date:1/28/2008

WELLESLEY HILLS, Mass., Jan. 28 /PRNewswire/ -- Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, today announced the completion the sale of the Company's fixed assets for in excess of $300,000 through an auction on January 24th. In addition, due to the high volume of requests for due diligence materials from prospective buyers for the purchase of the intellectual property, the Company has created an online datasite that allows access to confidential information pertinent to each of the three assets: Rifalazil, antibacterial NCEs, and superoxide dismutase small molecule mimetics.

The sale of ActivBiotics' assets is conducted through an Assignment for the Benefit of Creditors process. The bidding for the assets, which may be purchased separately or in combination, will be conducted on March 14, 2008. Any person interested in purchasing the assets or learning more about the bidding process should contact Mr. Joseph F. Finn, Jr., CPA.

Bidding packages, which contain technical information and the terms of sale, have been assembled and are ready to be distributed subject to a potential purchaser entering into a standard form confidentiality agreement.

Request for Further Information

Interested parties can obtain a bidder's package by contacting Joseph F. Finn, Jr., CPA (jffinnjr@earthlink.net, phone 781-237-8840), Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481-3613. For technical information or questions regarding the products, please contact Christo Shalish, cshalish@activbiotics.com.


'/>"/>
SOURCE ActivBiotics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
2. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
3. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
4. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
5. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
6. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
7. China Medical Technologies Completes Acquisition of BBE
8. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
9. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
10. Pharmos Corporation Completes Initial Closing of Private Placement
11. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan 19, 2017 Research and Markets has ... Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis and Industry ... ... the global market is projected to reach $15,737 million by 2022 ... 2016 to 2022. Omic technologies segment accounted for ...
(Date:1/19/2017)... , Jan. 19, 2017 /PRNewswire -- WuXi AppTec, ... open-access capability and technology platform, today announced that ... biology focused preclinical drug discovery contract research organization ... become a wholly-owned subsidiary of WuXi, and will ... and providing greater services. The acquisition will further ...
(Date:1/19/2017)... ... January 19, 2017 , ... November Research Group, ... biopharmaceutical and medical device manufacturers and regulators, is proud to announce the worldwide ... email client designed to provide product vigilance departments with the flexibility and ease ...
(Date:1/19/2017)... -- AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), a ... a majority-owned subsidiary of Intrexon Corporation (NYSE: ... of its common shares on the NASDAQ Stock Market ... "AquaBounty,s listing on NASDAQ represents an important milestone for ... U.S. markets as we advance plans for commercial production ...
Breaking Biology Technology:
(Date:1/11/2017)... Iowa , Jan. 11, 2017 Intoxalock, ... first with the release of its patent-pending calibration device. ... and reliably perform calibrations, securely upload data logs and ... for the customer. "Fighting drunk driving through ... for the public at large, but also for the ...
(Date:1/6/2017)... Jan. 5, 2017  SomaLogic announced today that ... Alliance" established by iCarbonX, the China ... a "Global Digital Health Ecosystem that can define ... of individual,s biological, behavioral and psychological data, the ... the companies, SomaLogic will provide proteomics data and ...
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017 /PRNewswire/ ... in performance biometric sensor technology, today announced the ... Benchmark™ sensor systems, the highly-accurate biometric sensor ... ® biometric technology, experience and expertise. The ... of Benchmark designed specifically for hearables, and Benchmark ...
Breaking Biology News(10 mins):